- Compass Pathways ( NASDAQ: CMPS ) said it launched a phase 2 trial of COMP360 psilocybin, administered with psychological support, in people with anorexia nervosa.
- Anorexia nervosa is an eating disorder characterized by an abnormally low body weight, fear of gaining weight and a distorted perception of weight.
- The study will will compare the effects of 25 mg and 1 mg COMP360 psilocybin when administered with psychological support, in 60 people with anorexia nervosa, across four research institutes in the U.K. and the U.S.
- Psilocybin is the psychedelic compound found in 'magic mushrooms.'
For further details see:
Compass launches mid-stage study of psilocybin therapy for anorexia